Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder

Annals of Pharmacotherapy

Volumn 34, Issue 2, 2000, Pages 147-153

  Fresquet, Anna ^a   Sust, Mariano ^a   Lloret, Antonio ^a   Murphy, Michael F ^b   Carter, Frederick J ^c   Campbell, Giedra M ^b   Marion Landais, Gaston ^b  

^a Laboratorios Dr Esteve SA   (Spain)

^b Worldwide Clinical Trials   (United States)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Generalized anxiety disorder; Lesopitron; Lorazepam

Indexed keywords

LESOPITRON; LORAZEPAM; PLACEBO;

ADULT; AMBLYOPIA; AMNESIA; ANXIETY NEUROSIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PAIN; PARESTHESIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

ADULT; AGORAPHOBIA; ANTI-ANXIETY AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; OUTPATIENTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RECURRENCE;

EID: 0033967497     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19041     Document Type: Article

References (20)

1. Farre AJ, Frigola J. Lesopitron dihydrochloride. Drugs Future 1994;19: 651-5.
2. Fisas MA, Colombo A, Gutierrez B, Colombo M, Farre AF. Activity of a series of non-benzodiazepine anxiolytic agents in a battery of conventional anxiety/conflict tests. In: Proceedings of the IV Reuniao conjunta das Sociedades Portuguesa e Espanhola de Farmacologia, Lisboa, Portugal, February 28-March 2, 1991.
3. Farre JA, Colombo A, Fisas MA, Gutierrez B, Fort M, Martinez L, et al. Pharmacological study of a series of non-benzodiazepine anxiolytic agents. In: Proceedings of the IV Reuniao conjunta das Sociedades Portuguesa e Espanhola de Farmacologia, Lisboa, Portugal, February 28-March 2, 1991.
4. 1A receptor ligand (abstract). Behav Pharmacol 1992;3(suppl 1):23.
5. 1A receptor ligand, E-4424, to inhibit aversive behaviour in the mouse, rat, and marmoset. J Pharmacol Exp Ther 1992;262:90-8.
6. Costall B, Domeney AM, Kelly ME, Naylor RJ. Preclinical evidence for the anxiolytic potential of E-4424 (abstract). Behav Pharmacol 1992;3 (suppl 1):19.
7. Serafini MT, Puig S, Garcia G, Farran R, Garcia A, Martinez L. In vitro metabolism of lesopitron by liver microsomes from different animal species (abstract). In: Proceedings of the European Conference on Specificity and Variability in Drug Metabolism, Besançon, France, May 1995.
8. Data on file. Laboratorios Dr. Esteve. S.A., Barcelona, Spain.
9. Sramek JJ, Fresquet A, Marion-Landais G, Hourani J, Jhee SS, Martinez L, et al. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. J Clin Psychopharmacol 1996;16:454-8.
10. Data on file. Interphase Clinical Research Unit, St. Mary's Hospital, Newport, Isle of Wight, UK.
11. Data on file. Institut Municipal d'Investigacio Medica, Barcelona, Spain.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994:432-6.
13. Basoglu M, Marks IM, Swinson RP, Noshirvani H, O'Sullivan G, Kuch K. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. J Affect Disord 1994;30:123-32.
14. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
15. Pollack MH, Otto MW, Sachs GS, Leon A, Shear MK, Deltito JA, et al. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord 1994;20:273-81.
16. Faravelli C, Albanesi G. Agoraphobia with panic attacks: 1-year prospective follow-up. Compr Psychiatry 1987;28:481-7.
17. Lelliott PT, Marks IM, Monteiro WO, Tsakiris F, Noshirvani H. Agoraphobics 5 years after imipramine and exposure: outcome and predictors. J Nerv Ment Dis 1987;175:599-605.
18. Scheibe G, Albus M. Predictors of outcome in panic disorder: a 5-year prospective follow-up study. J Affect Disord 1996;25:111-6.
19. Mavissakalian M, Michelson L. Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychiatry 1986;47:117-22.
20. Rapaport MH, Zisook S, Frevert T, Seymour S, Kelsoe JR, Judd LL. A comparison of descriptive variables for clinical patients and symptomatic volunteers with depressive disorders. J Clin Psychopharmacol 1996;16: 242-6.